- Home
- MRUS
MRUS
Merus N.V.
as 02-21-2025 4:00pm EST
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Upcoming Earnings Alert:
Get ready for potential market movements as Merus N.V. MRUS prepares to release earnings report on 26 Feb 2025.
| Founded: | 2003 | Country: | Netherlands |
| Employees: | N/A | City: | 3584 CM UTRECHT |
| Market Cap: | 2.8B | IPO Year: | 2016 |
| Target Price: | $85.67 | AVG Volume (30 days): | 513.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.77 - $61.61 | Next Earning Date: | 02-26-2025 |
| Revenue: | $35,932,000 | Revenue Growth: | -21.33% |
| Revenue Growth (this year): | -10.49% | Revenue Growth (next year): | 42.15% |
Latest Merus N.V. News
MRUS Breaking Stock News: Dive into MRUS Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
MT Newswires
4 days ago
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab
GlobeNewswire
4 days ago
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
GlobeNewswire
9 days ago
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
MT Newswires
9 days ago
Piper Sandler Initiates Merus at Overweight With $84 Price Target
MT Newswires
15 days ago
Wells Fargo Initiates Merus at Overweight With $91 Price Target
GlobeNewswire
16 days ago
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Insider Monkey
a month ago
Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential
Compare MRUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRUS Merus N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.